Tagrisso has been approved in the United States for adjuvant treatment of adults patients diagnosed early enough for the tumor to be surgically removed, and who have a mutation of the EGFR gene, AstraZeneca said.
AstraZeneca's Tagrisso gets broader US approval for lung cancer
By REUTERS
11/21/2024 11:43 PM
By REUTERS
11/21/2024 11:39 PM
By REUTERS
11/21/2024 11:36 PM
By REUTERS
11/21/2024 10:36 PM
By REUTERS
11/21/2024 09:44 PM
By REUTERS
11/21/2024 08:11 PM
By REUTERS
11/21/2024 07:28 PM
By REUTERS
11/21/2024 05:30 PM
By REUTERS
11/21/2024 05:20 PM
By REUTERS
11/21/2024 04:54 PM
By REUTERS
11/21/2024 04:48 PM